A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab
Abstract
What is this summary about?
This is a plain language summary of an article published in the Journal of Clinical Oncology in 2021. It describes the first results from 1 group of patients in the phase 1 CHRYSALIS study with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations. This part of the CHRYSALIS study (called cohort D) investigated the bispecific antibody amivantamab (brand name RYBREVANT®) in patients with non-small-cell lung cancer (NSCLC) with an EGFR ex20ins mutation. EGFR mutations are one of the most common causes of NSCLC tumors, with EGFR ex20ins mutations being more common among people of Asian descent. Patients who took part in this study had cancer that could not be removed by surgery, and whose cancer had worsened after receiving other forms of treatment, such as chemotherapy. Typically, patients with this type of mutation are difficult to treat or do not experience treatment response with commonly used therapies that target EGFR.
What were the results?
The CHRYSALIS study took place between May 27, 2016, and June 8, 2020, in select hospitals in the USA, Japan and South Korea. In cohort D, amivantamab showed promising results, with an overall response rate of 40%. This means that 4 of every 10 patients in CHRYSALIS cohort D had tumors that shrank or were no longer measurable.
Clinical Trial Registration:NCT02609776 (the CHRYSALIS Phase I Study) (ClinicalTrials.gov)
This is an abstract of the Plain Language Summary of Publication article.
To read the full Plain Language Summary of this article, click here to view the PDF.
Link to original article here
Acknowledgments
Janssen would like to thank the patients in this study, their caregivers, and all the study-center staff members who contributed. The authors would like to thank the reviewers of the article for the important feedback they provided in the development of this plain language summary publication. The authors would like to acknowledge Emanuela Kruser of Janssen Scientific Affairs, LLC, and Ashley D. Oney, MD, and Claire E. Brady, PharmD, of Lumanity Communications Inc. for medical writing support funded by Janssen Research & Development in accordance with Good Publications Practice 2022 guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460).
Financial & competing interests disclosure
A.S. held stock and other ownership interests in Lilly; received honoraria from CytomX Therapeutics, AstraZeneca/MedImmune, Merck, Takeda, Amgen, Janssen Oncology, Novartis, Bristol Myers Squibb, and Bayer; served as a consultant or advisor to Array BioPharma, Incyte, Amgen, Novartis, AstraZeneca/ MedImmune, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Merck, and Bristol Myers Squibb; and received research funding from Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Newlink Genetics, Incyte, AbbVie, Ignyta, LAM Therapeutics, Trovagene, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol Myers Squibb, Loxo, Arch Therapeutics, Gritstone Oncology, Plexxikon, Amgen, Daiichi Sankyo, ADC Therapeutics, Janssen Oncology, Mirati Therapeutics, and Rubius Therapeutics. N.G. is employed by AstraZeneca; served as a consultant or advisor for Roche, Lilly, Boehringer Ingelheim, AstraZeneca, Novartis, Pfizer, Bristol Myers Squibb, MSD, Takeda, GlaxoSmithKline, AbbVie, PharmaMar, Janssen, and Sanofi; received research funding from Roche, AstraZeneca, and Boehringer Ingelheim; and received travel, accommodations, and expenses from Roche, AstraZeneca, Bristol Myers Squibb, and MSD Oncology. M.K. served as a consultant or advisor to Roche, Achilles Therapeutics, Janssen, Seattle Genetics, Guardant Health, OM Pharma, and Bayer; received honoraria from Roche and Janssen; participated in speakers bureaus with Roche and Janssen; received research funding from Roche; and received travel, accommodations, and expenses from AstraZeneca, BerGenBio, and Immutep. K.P. served as a consultant or advisor to AstraZeneca, Lilly, Ono Pharmaceutical, Bristol Myers Squibb, MSD, Blueprint Medicines, Amgen, Merck KGaA, Loxo, AbbVie, Daiichi Sankyo, Boehringer Ingelheim, Johnson & Johnson, Eisai, and Puma Biotechnology; participated in speakers bureaus for Boehringer Ingelheim; and received funding from AstraZeneca and MSD Oncology. C.S. served as a consultant or advisor to AstraZeneca, Boehringer Ingelheim, and Genentech/Roche; received research funding from Celgene, Genentech/ Roche, Janssen, and MedImmune; and received travel, accommodations, and expenses from Genentech/Roche. L.D. has received payment or honoraria from Janssen. B.C.C. held leadership positions at Gencurix and Interpark Bio Convergence; held stock and other ownership interests in TheraCanVac, Gencurix, BridgeBio Therapeutics, KANAPH Therapeutics, Cyrus Therapeutics, and Interpark Bio Convergence; has been a consultant or advisor to Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Bristol Myers Squibb, Yuhan, Pfizer, Janssen, Takeda, MSD, Ono Pharmaceutical, Eli Lilly, MedPacto, Blueprint Medicines, KANAPH Therapeutics, BridgeBio Therapeutics, Cyrus Therapeutics, Guardant Health, and Oscotec; received research funding from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono Pharmaceutical, Dizal Pharma, MSD, AbbVie, MedPacto, GI Innovation, Eli Lilly, Blueprint Medicines, and Interpark Bio Convergence; has patents, royalties, or other intellectual property with Champions Oncology; and has a relationship with DAAN Biotherapeutics.
Open access
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
